Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
AbstractIn axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.
- Abstract views: 2179
- PDF: 461
Copyright (c) 2013 A. Spadaro, A. Scarno, A. Carboni, F.M. Perrotta, C. Catalano, E. Lubrano, G. Valesini
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.